Overview

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
This study compared the relative bioavailability (rate and extent of absorption) of Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited with that of Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd. Distributed by Parke-Davis, division of Warner-Lambert Co. following a single oral dose (1x800 mg tablet) in healthy adult volunteers under non-fasting conditions.
Phase:
N/A
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Gabapentin
gamma-Aminobutyric Acid